[go: up one dir, main page]

GB202306835D0 - Therapy - Google Patents

Therapy

Info

Publication number
GB202306835D0
GB202306835D0 GBGB2306835.6A GB202306835A GB202306835D0 GB 202306835 D0 GB202306835 D0 GB 202306835D0 GB 202306835 A GB202306835 A GB 202306835A GB 202306835 D0 GB202306835 D0 GB 202306835D0
Authority
GB
United Kingdom
Prior art keywords
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2306835.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adjutec Pharma AS
Original Assignee
Adjutec Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adjutec Pharma AS filed Critical Adjutec Pharma AS
Priority to GBGB2306835.6A priority Critical patent/GB202306835D0/en
Publication of GB202306835D0 publication Critical patent/GB202306835D0/en
Priority to PCT/EP2024/062876 priority patent/WO2024231518A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2306835.6A 2023-05-09 2023-05-09 Therapy Ceased GB202306835D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2306835.6A GB202306835D0 (en) 2023-05-09 2023-05-09 Therapy
PCT/EP2024/062876 WO2024231518A1 (en) 2023-05-09 2024-05-09 Combination therapy for bacterial infections comprising zinc-chelator, beta-lactam antibiotic and cyclic boronate beta-lactamase inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2306835.6A GB202306835D0 (en) 2023-05-09 2023-05-09 Therapy

Publications (1)

Publication Number Publication Date
GB202306835D0 true GB202306835D0 (en) 2023-06-21

Family

ID=86763227

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2306835.6A Ceased GB202306835D0 (en) 2023-05-09 2023-05-09 Therapy

Country Status (2)

Country Link
GB (1) GB202306835D0 (en)
WO (1) WO2024231518A1 (en)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040225004A1 (en) 2003-02-06 2004-11-11 Bioresponse, Llc Combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions
WO2006043153A2 (en) 2004-10-20 2006-04-27 Michel Xilinas Use of zinc and copper chelators for the treatment of viral diseases
WO2009140215A2 (en) 2008-05-11 2009-11-19 Geraghty, Erin Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds
US20110189260A1 (en) 2008-05-30 2011-08-04 University Of Cincinnati Use of zinc chelators to inhibit biofilm formation
CA2780756A1 (en) 2009-11-23 2011-05-26 Prothera, Inc. Compositions and methods comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions
BR112013003045B1 (en) 2010-08-10 2021-08-31 Rempex Pharmaceuticals, Inc. Compound and its use, pharmaceutical composition, sterile container and method for preparing pharmaceutical composition for administration
KR102147420B1 (en) 2012-12-07 2020-08-25 베나토알엑스 파마슈티컬스, 인크. Beta-lactamase inhibitors
GB201317619D0 (en) 2013-10-04 2013-11-20 Uni I Oslo Compounds
KR102396753B1 (en) 2014-06-11 2022-05-12 베나토알엑스 파마슈티컬스, 인크. Beta-lactamase inhibitors
US10294249B2 (en) 2016-06-30 2019-05-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
GB201613946D0 (en) 2016-08-15 2016-09-28 Univ Oslo Compounds

Also Published As

Publication number Publication date
WO2024231518A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
CA221425S (en) Therapy eye-mask
GB202113079D0 (en) New therapy
GB202103164D0 (en) Therapy
GB202002639D0 (en) Therapy
IL319599A (en) Combination therapy
IL318268A (en) Combination therapy
GB202111035D0 (en) Therapy
GB202108303D0 (en) Therapy
GB202315877D0 (en) Therapy
GB202306826D0 (en) Therapy
GB202306833D0 (en) Therapy
GB202306835D0 (en) Therapy
GB202303026D0 (en) Therapy
GB202219335D0 (en) Therapy
GB202218595D0 (en) Therapy
GB202215997D0 (en) Therapy
GB202214514D0 (en) Therapy
GB202318311D0 (en) Combination therapy
GB202317996D0 (en) Combination therapy
GB202316168D0 (en) Combination therapy
GB202315149D0 (en) Combination therapy
GB202314243D0 (en) Combination therapy
GB202314157D0 (en) Combination therapy
GB202306663D0 (en) Combination therapy
GB202218974D0 (en) Combination therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)